Exelixis EXEL Accrued collaboration liabilities
Accrued collaboration liabilities at other companies
Other financials
Where this comes from
Reported directly by Exelixis in its filing.
Tagged under the XBRL concept exel:AccruedCollaborationLiabilityCurrent.
The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Exelixis's accrued collaboration liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Exelixis's accrued collaboration liabilities?
- Exelixis (EXEL) reported accrued collaboration liabilities of $28.33M in Q1 2026.
- How has Exelixis's accrued collaboration liabilities changed year-over-year?
- Exelixis's accrued collaboration liabilities increased by 11.1% year-over-year, from $25.49M to $28.33M.
- What is the long-term trend for Exelixis's accrued collaboration liabilities?
- Over 5 years (2020 to 2025), Exelixis's accrued collaboration liabilities has grown at a 12.8% compound annual growth rate (CAGR), from $12.46M to $22.78M.
- What does accrued collaboration liabilities mean?
- The short-term financial obligations owed to strategic partners under collaboration agreements.
- How do you interpret accrued collaboration liabilities?
- Increases reflect active, high-intensity collaboration efforts, while decreases suggest the settlement of shared costs or changes in partnership scope.
- How does accrued collaboration liabilities compare across companies?
- Highly specific to biopharma companies that rely on co-development or co-commercialization models with larger partners.